Sign inJoin waitlistJoin the waitlist

Edward P. Gelmann

Deputy Director for Clinical Research

Credentials: · · · · · · ·

History

Columbia University Medical Center
Present
Columbia University Medical Center
Present
CUMC
Present

National Cancer Institute
University of Chicago Hospitals and Clinics
Stanford University School of Medicine
1976
Yale College

Research

Mortality results from a randomized prostate-cancer screening trial
New England Journal of Medicine · 2009 · 2,143 citations
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations
Review · Annals of Internal Medicine · 1984 · Last of 7 authors · 907 citations
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
Nature Genetics · 2007 · 892 citations

Henry Masur
17 papers
HL
Henry Lane
13 papers
Marc Lippman
12 papers
Anthony Fauci
11 papers
GA
Gerald Andriole
11 papers · 3 as a resident
DR
Douglas Reding
10 papers
BK
Barnett Kramer
9 papers
GW
George Wilding
9 papers
DL
Dan Longo
8 papers
David Crawford
8 papers
RS
Ronald Steis
8 papers · 8 as a fellow
Alain Rook
7 papers · 7 as a fellow

Grants

University of Arizona Cancer Center - Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $244.3K · University of Arizona
1997–2027
DYRK1B Inhibition for Prostate Cancer
National Center for Advancing Translational Sciences · R03
Contact PI · $153.5K · University of Arizona
2023–2024
Molecular Mechanisms of Prostate Cancer Initiation
National Cancer Institute · P01
Project lead · $971.4K · Columbia University Health Sciences
2011–2017
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $2.1M · Columbia University Health Sciences
1997–2014

Clinical trials

Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer
Principal investigator · Completed · Phase 1
Columbia University
2005–2013
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
Study chair · Completed · Phase 2
Alliance for Clinical Trials in Oncology
2000–2006
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2039
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037